Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
ZacksAkero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.